Biotech News
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases.
Open original release
Related news
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-06-09 12:00 EST
GSK enters agreement to acquire Nuvalent, Inc.
KYMRKymera2026-05-05 11:00 EST
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
SRPTSarepta Therapeutics2026-06-01 20:30 EST
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
BMYBMYBristol-Myers Squibb Company2026-05-20 10:59 EST
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
SRPTSarepta Therapeutics2026-05-13 20:30 EST
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
KYMRKymera2026-06-08 11:00 EST
Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses
REGNRegeneron Pharmaceuticals2026-06-04 11:00 EST
Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
NTLAIntellia2026-06-01 11:30 EST
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
GSK plc
GSK is a global biopharmaceutical company with meaningful exposure to vaccines, respiratory medicines, immunology, and infectious disease. The company has been reshaping its portfolio around stronger innovation and higher-growth specialty products.
Recent company news
GSKGSK plc2026-07-28 12:05 EST
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
GSKGSK plc2026-07-22 11:21 EST
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
Stock data
- Close
- 51.98 USD
- Market cap
- 98.26B USD
- Exchange
- NYSE
- Sector
- Vaccines, Biopharma, Gene Therapy, Antibody Drugs, Small Molecule Drugs, Nucleic Acid Drugs
- Location
- United States